文献速递神经MR

ARCADIA-MRI中颅内出血的MRI表现:ARCADIA试验的一项辅助研究

MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-02-03

ARCADIA-MRI辅助研究纳入阿哌沙班组79例与阿司匹林组95例隐源性卒中患者,比较基线及随访MRI。随访中新发颅内出血、微出血及皮质表面铁沉积在两组间均无显著差异(均P > .05),提示阿哌沙班与阿司匹林在出血性病灶方面表现相似。

要点

  • 随访MRI新发颅内出血(>10 mm):阿哌沙班组5.1% vs 阿司匹林组6.4%,差异无统计学意义。
  • 微出血(≤10 mm):阿哌沙班组7.8% vs 阿司匹林组10.8%,差异无统计学意义。
  • 皮质表面铁沉积:阿哌沙班组7.7% vs 阿司匹林组12.9%,差异无统计学意义。

核心结论

  • 在ARCADIA-MRI探索性分析中,随机接受阿哌沙班与阿司匹林的患者随访MRI新发出血事件表现相似。

研究设计与样本

  • ARCADIA-MRI为随机对照试验ARCADIA的辅助研究,纳入无MRI禁忌且符合认知测试条件的随机化患者,随访4个月至5.3年(中位27个月)。

关键影像表现/征象

  • 新发颅内出血定义为病灶>10 mm,微出血定义为≤10 mm,并评估皮质表面铁沉积。
  • 两组基线MRI表现相似。
  • 随访MRI新发出血事件在两组间无显著差异(均P > .05)。

诊断标准与关键数值

  • 颅内出血:阿哌沙班组5.1% vs 阿司匹林组6.4%,P > .05。
  • 微出血:阿哌沙班组7.8% vs 阿司匹林组10.8%,P > .05。
  • 皮质表面铁沉积:阿哌沙班组7.7% vs 阿司匹林组12.9%,P > .05。

临床应用与阅片要点

  • 原文未据本研究结果给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The ARCADIA-MRI study, an ancillary study to the randomized Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, reported that the risk of incident nonlacunar covert infarcts was lower in the apixaban group than in the aspirin group. This article presents the additional, prespecified, exploratory outcomes beyond the primary article, specifically examining the effect of apixaban on hemorrhagic lesions on MRI.

MATERIALS AND METHODS: The ARCADIA-MRI study was conducted in conjunction with ARCADIA trial visits, with follow-up durations ranging from 4 months to 5.3 years (median, 27 months). It included randomized patients who were eligible for cognitive testing and lacked MRI contraindications. Two experienced raters, blinded to treatment assignments, independently evaluated the baseline and follow-up MRI scans. The radiologic end points of this analysis were incident intracranial hemorrhage (>10 mm), microbleeds (≤10 mm), and superficial siderosis.

RESULTS: MRI outcomes were compared between the 79 patients in the apixaban group and 95 in the aspirin group with both baseline and follow-up MRIs available. The treatment groups had similar baseline MRI findings. On the follow-up MRIs, the findings of incident bleeding events were similar between the treatment groups (all, P > .05): Intracranial hemorrhage occurred in 5.1% of patients in the apixaban group compared with 6.4% of patients in the aspirin group; microbleeds, 7.8% in the apixaban group and 10.8% in the aspirin group; and cortical superficial siderosis, in 7.7% of apixaban group and 12.9% in the aspirin group.

CONCLUSIONS: In an exploratory analysis of the ARCADIA-MRI substudy, MRI findings of incident bleeding events were similar in patients randomized to receive apixaban and aspirin.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Chen H, Lansberg M, Zhu G, et al. MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial. AJNR Am J Neuroradiol. 2026. PMID: 40769726. doi:10.3174/ajnr.A8955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。